Vectors and Methods to Increase Immunogenicity during DNA Vaccination

免疫原诱导的保护性，疾病保留CD 8 + T细胞反应是VRC研究工作的主要重点。 DNA疫苗是目前候选疫苗的主要平台。虽然DNA免疫原可以产生CD 8 + CTL应答，但需要施用大量DNA来诱导免疫。这些研究旨在确定将提高DNA免疫效率的干预措施，并优化每种干预措施的条件。 随着增加疫苗DNA的摄取和/或表达的程序的确定，将需要更少的DNA的管理，使DNA疫苗的使用更广泛地适用，特别是在发展中国家。 此外，将评价表达匹配的密码子修饰的病毒蛋白的基于载体的免疫原诱导病毒特异性免疫应答的相对能力。 具体而言，将使用鼠初免-攻击模型比较由每种载体诱导的免疫应答的幅度和质量。

Immunogens inducing protective, disease-sparing CD8+ T cell responses are a primary focus of research efforts at the VRC. DNA vaccines are the chief platform of vaccine candidates currently. While DNA immunogens can generate CD8+ CTL responses, administration of large quantities of DNA is required to induce immunity. These studies are designed to identify interventions that will increase the efficiency of DNA immunization and to optimize the conditions of each intervention. With the identification of procedures that increase the uptake and/or expression of vaccine DNA, the administration of less DNA would be required, making the use of DNA vaccines more widely applicable, particularly in developing countries. Additionally, vector-based immunogens expressing matched codon-modified viral proteins will be evaluated for their relative abilities to induce virus-specific immune responses. Specifically, the magnitude and the quality of the immune responses induced by each vector will be compared using murine prime-challenge models.